Literature DB >> 6687401

Ophthalmopathy of Graves' disease.

C Gorman.   

Abstract

Entities:  

Mesh:

Year:  1983        PMID: 6687401     DOI: 10.1056/NEJM198302243080811

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Volumetric analysis of CT orbital images.

Authors:  L Lutzemberger; O Salvetti
Journal:  Med Biol Eng Comput       Date:  1998-11       Impact factor: 2.602

2.  Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine.

Authors:  A Barth; P Probst; H Bürgi
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

3.  Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease.

Authors:  W M Wiersinga; T Smit; R van der Gaag; L Koornneef
Journal:  J Endocrinol Invest       Date:  1988-09       Impact factor: 4.256

4.  Clinical significance of a new autoantibody against a human eye muscle soluble antigen, detected by immunofluorescence.

Authors:  M Mengistu; E Laryea; A Miller; J R Wall
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

5.  Antithyroglobulin monoclonal and autoantibodies cross-react with an orbital connective tissue membrane antigen: a possible mechanism for the association of ophthalmopathy with autoimmune thyroid disorders.

Authors:  T Kuroki; J Ruf; L Whelan; A Miller; J R Wall
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

6.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

7.  Antibody-dependent cell-mediated cytotoxicity against human eye muscle cells and orbital fibroblasts in Graves' ophthalmopathy--roles of class II MHC antigen expression and gamma-interferon action of effector and target cells.

Authors:  Y Hiromatsu; H Fukazawa; J How; J R Wall
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.